记者从公司获悉，叮当健康(09886.HK)正在持续加码创新药布局，已与亿腾医药达成重要合作。近日， 叮当健康旗下药房新上架抗肿瘤1类创新药盐酸来罗西利片，已完成首单服务。该药于今年5月29日获批 上市。 据介绍，自2025年以来，叮当健康推出"新特药.生命方舟计划"，相继上架包括记能达、艾维达在内的 多款创新药，有效提升了患者的用药可及性与依从性。 从经营业绩看，8月22日晚间，叮当健康发布的2025年上半年业绩报告显示，上半年，公司录得收入 23.27亿元，同比增长2.6%。毛利为8.16亿元，毛利率为35%。期内亏损5202万元，相较于2024年同期亏 损收窄42.1%；经调整后的净利润亏损575.9万元，相较于2024年同期亏损收窄78.2%。 此外，叮当健康在强化药品供应端的同时，也加速推进从智慧仓配到医保支付的全链路部署：已构建华 北、华中、华东、华南四大智能仓，并在北京、上海、深圳建立冷链到家服务能力；在多个城市打通医 保在线支付，并积极探索商业保险支付方式，致力于解决患者支付难题。 近年来，随着人口老龄化加剧与健康意识提升，创新药市场已成为医药行业的核心增长引擎。叮当健康 借此趋势，充分发挥其 ...

Group 1 - The core viewpoint highlights the rapid enhancement of the "first industry" capability in Suzhou Industrial Park, driven by precise policy support and deep capital empowerment, particularly in the biopharmaceutical sector [1] - In 2023, six innovative Class I drugs were approved for market release in the park, accounting for approximately 20% of the national total, showcasing the growing "innovation source" effect in biomedicine [2] - The park has attracted over 2,000 related enterprises since 2006, with a projected output value of 165.5 billion yuan in 2024, emphasizing its strategic focus on biomedicine and health industries [1] Group 2 - The "Biopharmaceutical and Health Industry Leap Action Plan (2025-2027)" aims to cultivate five international leading enterprises, 50 leading companies in niche markets, and 100 key products with annual sales exceeding 100 million yuan by 2027 [1] - The capital market has shown active performance, with companies like Sifen Technology and Ascentage Pharma successfully listing on various stock exchanges, indicating strong market confidence in the park's biopharmaceutical capabilities [2] - The integration of artificial intelligence in research and development is reshaping the paradigm, with significant improvements in efficiency and cost reduction in drug development processes [3]